Obsessive-compulsive Disorder
📧 Sign up to get email alerts when something new happens for Obsessive-compulsive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-08-18FDA Approved: FLUOXETINE — Supplemental Application (ScieGen Pharmaceuticals, Inc)
FDA approved a supplemental application for a ScieGen Pharmaceuticals generic fluoxetine product under anANDA process.
-
FDA approval · 2023-08-18FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Alvogen, Inc.)
FDA approved a supplemental application for sertraline hydrochloride (Alvogen), resulting in labeling changes to the approved NDA.
-
FDA approval · 2023-08-18FDA Approved: FLUOXETINE HYDROCHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for fluoxetine hydrochloride submitted by Upsher-Smith Laboratories, LLC.
-
FDA approval · 2023-08-18FDA Approved: FLUOXETINE HYDROCHLORIDE — Supplemental Application (Dr.Reddy's Laboratories Limited)
The FDA approved a supplemental application for fluoxetine hydrochloride from Dr. Reddy's Laboratories Limited. This is an approved amendmen…
-
FDA approval · 2023-08-18FDA Approved: PAROXETINE — Supplemental Application (Padagis US LLC)
The FDA approved a supplemental application for paroxetine submitted by Padagis US LLC. This action represents an additional regulatory appr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-08-18FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approves a supplemental application for fluvoxamine maleate submitted by ANI Pharmaceuticals, Inc.
-
FDA approval · 2023-08-18FDA Approved: FLUOXETINE HYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for fluoxetine hydrochloride from Alembic Pharmaceuticals Limited.
-
FDA approval · 2023-08-10FDA Approved: FLUOXETINE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for fluoxetine from Torrent Pharmaceuticals Limited, enabling the generic antidepressant to be manuf…
-
CLINICAL_TRIALS trial_result · 2023-07-03Clinical Trial Update: Effects of Ondansetron in Obsessive-compulsive and Tic Disorders [Phase 4]
Phase 4 trial evaluating ondansetron for obsessive-compulsive disorder and tic disorders (including Tourette syndrome) has completed, with r…
-
CLINICAL_TRIALS trial_result · 2023-06-08Clinical Trial Update: Transcranial Magnetic Stimulation (TMS) in Obsessive Compulsive Disorder (OCD): Mechanisms and Biomarkers [NA]
This clinical trial update reports completed results on transcranial magnetic stimulation (TMS) for obsessive-compulsive disorder, including…
-
CLINICAL_TRIALS trial_result · 2023-06-02Clinical Trial Update: Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder [Phase 2, Phase 3]
Clinical trial update on Troriluzole (BHV-4157) in adults with obsessive-compulsive disorder notes Phase 2 and Phase 3 studies completed and…
-
CLINICAL_TRIALS withdrawal · 2023-04-18Clinical Trial Update: Brief Intervention for OCD Fears [Phase 4]
Phase 4 clinical trial for Brief Intervention for OCD Fears has been withdrawn.
-
FDA approval · 2023-03-31FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
FDA approved a supplemental application for Granules Pharmaceuticals' sertraline hydrochloride generic product, enabling its marketing in th…
-
FDA approval · 2023-03-23FDA Approved: PAROXETINE — Supplemental Application (Modavar Pharmaceuticals LLC)
FDA approved a supplemental application for generic paroxetine filed by Modavar Pharmaceuticals LLC under ANDA212645.
-
FDA approval · 2023-03-20FDA Approved: CLOMIPRAMINE HYDROCHLORIDE — Original Application (Aurobindo Pharma Limited)
FDA approved the original abbreviated new drug application for clomipramine hydrochloride (generic) by Aurobindo Pharma Limited.
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: rTMS Over the Supplementary Motor Area for Treatment-resistant Obsessive-compulsive Disorder. [Phase 1, Phase 2]
A clinical trial update explores repetitive transcranial magnetic stimulation over the supplementary motor area for treatment-resistant obse…
-
FDA approval · 2023-01-31FDA Approved: PAROXETINE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for paroxetine from ANI Pharmaceuticals, indicating an approved change to the product (e.g., lab…
-
CLINICAL_TRIALS trial_result · 2023-01-26Clinical Trial Update: Ventral Capsulotomy for Intractable OCD [Phase 3]
Phase 3 clinical trial update for ventral capsulotomy as a treatment for intractable obsessive-compulsive disorder (OCD) is currently enroll…
-
FDA approval · 2023-01-25FDA Approved: ZOLOFT — Supplemental Application (ROERIG)
The FDA approved a supplemental application for Zoloft (sertraline hydrochloride) filed by Roerig.
-
FDA approval · 2022-12-19FDA Approved: FLUVOXAMINE MALEATE — Supplemental Application (Apotex Corp)
FDA approved Apotex Corp's supplemental application for fluvoxamine maleate, i.e., the generic fluvoxamine product.
-
CLINICAL_TRIALS trial_result · 2022-12-16Clinical Trial Update: Adjunctive Celecoxib in Childhood-onset OCD Study [Phase 2]
Phase 2 clinical trial evaluating adjunctive celecoxib for pediatric obsessive-compulsive disorder.
-
FDA approval · 2022-12-05FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA has approved Lupin Pharmaceuticals' supplemental application for sertraline hydrochloride, allowing the generic to be marketed as part o…
-
FDA approval · 2022-11-29FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for escitalopram oxalate (a generic version of Lexapro), enabling market entry…
-
FDA approval · 2022-11-15FDA Approved: FLUOXETINE HYDROCHLORIDE — Original Application (Upsher-Smith Laboratories, LLC)
The FDA approved Upsher-Smith's fluoxetine hydrochloride as an original generic application, allowing the generic product to be marketed wit…
-
FDA approval · 2022-11-09FDA Approved: FLUOXETINE HYDROCHLORIDE — Original Application (ANI Pharmaceuticals, Inc.)
FDA approves ANI Pharmaceuticals' original application for fluoxetine hydrochloride, a generic version of fluoxetine.